<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Defense Threat Reduction Agency &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/defense-threat-reduction-agency/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 23:04:35 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Defense Threat Reduction Agency &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Mount Sinai Wins $20.7 Million Deal to Build a Next-Generation Respiratory Vaccine Platform</title>
		<link>https://bioengineer.org/mount-sinai-wins-20-7-million-deal-to-build-a-next-generation-respiratory-vaccine-platform/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 23:04:35 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[antigen presentation]]></category>
		<category><![CDATA[Defense Threat Reduction Agency]]></category>
		<category><![CDATA[H5N1]]></category>
		<category><![CDATA[influenza]]></category>
		<category><![CDATA[intranasal delivery]]></category>
		<category><![CDATA[macrophages]]></category>
		<category><![CDATA[Mount Sinai]]></category>
		<category><![CDATA[mRNA vaccine]]></category>
		<category><![CDATA[pulse immunization]]></category>
		<category><![CDATA[RAVEN program]]></category>
		<category><![CDATA[respiratory viruses]]></category>
		<category><![CDATA[VITAL]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=433027</guid>

					<description><![CDATA[Mount Sinai researchers have received a five-year, $20.7 million agreement to develop the VITAL vaccine platform, beginning with an intranasal H5N1 mRNA prototype designed to target antigen expression to respiratory immune cells.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">433027</post-id>	</item>
	</channel>
</rss>
